Copyright Reports & Markets. All rights reserved.

Global Hormone Refractory Prostate Cancer (HRPCA) Market Size, Status and Forecast 2021-2027

Request for Sample of this report
Buy now

1 Report Overview

  • 1.1 Study Scope
  • 1.2 Market Analysis by Type
    • 1.2.1 Global Hormone Refractory Prostate Cancer (HRPCA) Market Size Growth Rate by Type: 2016 VS 2021 VS 2027
    • 1.2.2 Cytotoxic Agents
    • 1.2.3 Anti-Androgens
    • 1.2.4 Vaccines
    • 1.2.5 Radio-Pharmaceuticals
  • 1.3 Market by Application
    • 1.3.1 Global Hormone Refractory Prostate Cancer (HRPCA) Market Share by Application: 2016 VS 2021 VS 2027
    • 1.3.2 Hospitals
    • 1.3.3 Ambulatory Surgical Centers
    • 1.3.4 Specialty Clinics
    • 1.3.5 Others
  • 1.4 Study Objectives
  • 1.5 Years Considered

2 Global Growth Trends

  • 2.1 Global Hormone Refractory Prostate Cancer (HRPCA) Market Perspective (2016-2027)
  • 2.2 Hormone Refractory Prostate Cancer (HRPCA) Growth Trends by Regions
    • 2.2.1 Hormone Refractory Prostate Cancer (HRPCA) Market Size by Regions: 2016 VS 2021 VS 2027
    • 2.2.2 Hormone Refractory Prostate Cancer (HRPCA) Historic Market Share by Regions (2016-2021)
    • 2.2.3 Hormone Refractory Prostate Cancer (HRPCA) Forecasted Market Size by Regions (2022-2027)
  • 2.3 Hormone Refractory Prostate Cancer (HRPCA) Industry Dynamic
    • 2.3.1 Hormone Refractory Prostate Cancer (HRPCA) Market Trends
    • 2.3.2 Hormone Refractory Prostate Cancer (HRPCA) Market Drivers
    • 2.3.3 Hormone Refractory Prostate Cancer (HRPCA) Market Challenges
    • 2.3.4 Hormone Refractory Prostate Cancer (HRPCA) Market Restraints

3 Competition Landscape by Key Players

  • 3.1 Global Top Hormone Refractory Prostate Cancer (HRPCA) Players by Revenue
    • 3.1.1 Global Top Hormone Refractory Prostate Cancer (HRPCA) Players by Revenue (2016-2021)
    • 3.1.2 Global Hormone Refractory Prostate Cancer (HRPCA) Revenue Market Share by Players (2016-2021)
  • 3.2 Global Hormone Refractory Prostate Cancer (HRPCA) Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
  • 3.3 Players Covered: Ranking by Hormone Refractory Prostate Cancer (HRPCA) Revenue
  • 3.4 Global Hormone Refractory Prostate Cancer (HRPCA) Market Concentration Ratio
    • 3.4.1 Global Hormone Refractory Prostate Cancer (HRPCA) Market Concentration Ratio (CR5 and HHI)
    • 3.4.2 Global Top 10 and Top 5 Companies by Hormone Refractory Prostate Cancer (HRPCA) Revenue in 2020
  • 3.5 Hormone Refractory Prostate Cancer (HRPCA) Key Players Head office and Area Served
  • 3.6 Key Players Hormone Refractory Prostate Cancer (HRPCA) Product Solution and Service
  • 3.7 Date of Enter into Hormone Refractory Prostate Cancer (HRPCA) Market
  • 3.8 Mergers & Acquisitions, Expansion Plans

4 Hormone Refractory Prostate Cancer (HRPCA) Breakdown Data by Type

  • 4.1 Global Hormone Refractory Prostate Cancer (HRPCA) Historic Market Size by Type (2016-2021)
  • 4.2 Global Hormone Refractory Prostate Cancer (HRPCA) Forecasted Market Size by Type (2022-2027)

5 Hormone Refractory Prostate Cancer (HRPCA) Breakdown Data by Application

  • 5.1 Global Hormone Refractory Prostate Cancer (HRPCA) Historic Market Size by Application (2016-2021)
  • 5.2 Global Hormone Refractory Prostate Cancer (HRPCA) Forecasted Market Size by Application (2022-2027)

6 North America

  • 6.1 North America Hormone Refractory Prostate Cancer (HRPCA) Market Size (2016-2027)
  • 6.2 North America Hormone Refractory Prostate Cancer (HRPCA) Market Size by Type
    • 6.2.1 North America Hormone Refractory Prostate Cancer (HRPCA) Market Size by Type (2016-2021)
    • 6.2.2 North America Hormone Refractory Prostate Cancer (HRPCA) Market Size by Type (2022-2027)
    • 6.2.3 North America Hormone Refractory Prostate Cancer (HRPCA) Market Size by Type (2016-2027)
  • 6.3 North America Hormone Refractory Prostate Cancer (HRPCA) Market Size by Application
    • 6.3.1 North America Hormone Refractory Prostate Cancer (HRPCA) Market Size by Application (2016-2021)
    • 6.3.2 North America Hormone Refractory Prostate Cancer (HRPCA) Market Size by Application (2022-2027)
    • 6.3.3 North America Hormone Refractory Prostate Cancer (HRPCA) Market Size by Application (2016-2027)
  • 6.4 North America Hormone Refractory Prostate Cancer (HRPCA) Market Size by Country
    • 6.4.1 North America Hormone Refractory Prostate Cancer (HRPCA) Market Size by Country (2016-2021)
    • 6.4.2 North America Hormone Refractory Prostate Cancer (HRPCA) Market Size by Country (2022-2027)
    • 6.4.3 United States
    • 6.4.3 Canada

7 Europe

  • 7.1 Europe Hormone Refractory Prostate Cancer (HRPCA) Market Size (2016-2027)
  • 7.2 Europe Hormone Refractory Prostate Cancer (HRPCA) Market Size by Type
    • 7.2.1 Europe Hormone Refractory Prostate Cancer (HRPCA) Market Size by Type (2016-2021)
    • 7.2.2 Europe Hormone Refractory Prostate Cancer (HRPCA) Market Size by Type (2022-2027)
    • 7.2.3 Europe Hormone Refractory Prostate Cancer (HRPCA) Market Size by Type (2016-2027)
  • 7.3 Europe Hormone Refractory Prostate Cancer (HRPCA) Market Size by Application
    • 7.3.1 Europe Hormone Refractory Prostate Cancer (HRPCA) Market Size by Application (2016-2021)
    • 7.3.2 Europe Hormone Refractory Prostate Cancer (HRPCA) Market Size by Application (2022-2027)
    • 7.3.3 Europe Hormone Refractory Prostate Cancer (HRPCA) Market Size by Application (2016-2027)
  • 7.4 Europe Hormone Refractory Prostate Cancer (HRPCA) Market Size by Country
    • 7.4.1 Europe Hormone Refractory Prostate Cancer (HRPCA) Market Size by Country (2016-2021)
    • 7.4.2 Europe Hormone Refractory Prostate Cancer (HRPCA) Market Size by Country (2022-2027)
    • 7.4.3 Germany
    • 7.4.4 France
    • 7.4.5 U.K.
    • 7.4.6 Italy
    • 7.4.7 Russia
    • 7.4.8 Nordic

8 Asia-Pacific

  • 8.1 Asia-Pacific Hormone Refractory Prostate Cancer (HRPCA) Market Size (2016-2027)
  • 8.2 Asia-Pacific Hormone Refractory Prostate Cancer (HRPCA) Market Size by Type
    • 8.2.1 Asia-Pacific Hormone Refractory Prostate Cancer (HRPCA) Market Size by Type (2016-2021)
    • 8.2.2 Asia-Pacific Hormone Refractory Prostate Cancer (HRPCA) Market Size by Type (2022-2027)
    • 8.2.3 Asia-Pacific Hormone Refractory Prostate Cancer (HRPCA) Market Size by Type (2016-2027)
  • 8.3 Asia-Pacific Hormone Refractory Prostate Cancer (HRPCA) Market Size by Application
    • 8.3.1 Asia-Pacific Hormone Refractory Prostate Cancer (HRPCA) Market Size by Application (2016-2021)
    • 8.3.2 Asia-Pacific Hormone Refractory Prostate Cancer (HRPCA) Market Size by Application (2022-2027)
    • 8.3.3 Asia-Pacific Hormone Refractory Prostate Cancer (HRPCA) Market Size by Application (2016-2027)
  • 8.4 Asia-Pacific Hormone Refractory Prostate Cancer (HRPCA) Market Size by Region
    • 8.4.1 Asia-Pacific Hormone Refractory Prostate Cancer (HRPCA) Market Size by Region (2016-2021)
    • 8.4.2 Asia-Pacific Hormone Refractory Prostate Cancer (HRPCA) Market Size by Region (2022-2027)
    • 8.4.3 China
    • 8.4.4 Japan
    • 8.4.5 South Korea
    • 8.4.6 Southeast Asia
    • 8.4.7 India
    • 8.4.8 Australia

9 Latin America

  • 9.1 Latin America Hormone Refractory Prostate Cancer (HRPCA) Market Size (2016-2027)
  • 9.2 Latin America Hormone Refractory Prostate Cancer (HRPCA) Market Size by Type
    • 9.2.1 Latin America Hormone Refractory Prostate Cancer (HRPCA) Market Size by Type (2016-2021)
    • 9.2.2 Latin America Hormone Refractory Prostate Cancer (HRPCA) Market Size by Type (2022-2027)
    • 9.2.3 Latin America Hormone Refractory Prostate Cancer (HRPCA) Market Size by Type (2016-2027)
  • 9.3 Latin America Hormone Refractory Prostate Cancer (HRPCA) Market Size by Application
    • 9.3.1 Latin America Hormone Refractory Prostate Cancer (HRPCA) Market Size by Application (2016-2021)
    • 9.3.2 Latin America Hormone Refractory Prostate Cancer (HRPCA) Market Size by Application (2022-2027)
    • 9.3.3 Latin America Hormone Refractory Prostate Cancer (HRPCA) Market Size by Application (2016-2027)
  • 9.4 Latin America Hormone Refractory Prostate Cancer (HRPCA) Market Size by Country
    • 9.4.1 Latin America Hormone Refractory Prostate Cancer (HRPCA) Market Size by Country (2016-2021)
    • 9.4.2 Latin America Hormone Refractory Prostate Cancer (HRPCA) Market Size by Country (2022-2027)
    • 9.4.3 Mexico
    • 9.4.4 Brazil

10 Middle East & Africa

  • 10.1 Middle East & Africa Hormone Refractory Prostate Cancer (HRPCA) Market Size (2016-2027)
  • 10.2 Middle East & Africa Hormone Refractory Prostate Cancer (HRPCA) Market Size by Type
    • 10.2.1 Middle East & Africa Hormone Refractory Prostate Cancer (HRPCA) Market Size by Type (2016-2021)
    • 10.2.2 Middle East & Africa Hormone Refractory Prostate Cancer (HRPCA) Market Size by Type (2022-2027)
    • 10.2.3 Middle East & Africa Hormone Refractory Prostate Cancer (HRPCA) Market Size by Type (2016-2027)
  • 10.3 Middle East & Africa Hormone Refractory Prostate Cancer (HRPCA) Market Size by Application
    • 10.3.1 Middle East & Africa Hormone Refractory Prostate Cancer (HRPCA) Market Size by Application (2016-2021)
    • 10.3.2 Middle East & Africa Hormone Refractory Prostate Cancer (HRPCA) Market Size by Application (2022-2027)
    • 10.3.3 Middle East & Africa Hormone Refractory Prostate Cancer (HRPCA) Market Size by Application (2016-2027)
  • 10.4 Middle East & Africa Hormone Refractory Prostate Cancer (HRPCA) Market Size by Country
    • 10.4.1 Middle East & Africa Hormone Refractory Prostate Cancer (HRPCA) Market Size by Country (2016-2021)
    • 10.4.2 Middle East & Africa Hormone Refractory Prostate Cancer (HRPCA) Market Size by Country (2022-2027)
    • 10.4.3 Turkey
    • 10.4.4 Saudi Arabia
    • 10.4.5 UAE

11 Key Players Profiles

  • 11.1 Astellas Inc
    • 11.1.1 Astellas Inc Company Details
    • 11.1.2 Astellas Inc Business Overview
    • 11.1.3 Astellas Inc Hormone Refractory Prostate Cancer (HRPCA) Introduction
    • 11.1.4 Astellas Inc Revenue in Hormone Refractory Prostate Cancer (HRPCA) Business (2016-2021)
    • 11.1.5 Astellas Inc Recent Development
  • 11.2 Sanofi S.A
    • 11.2.1 Sanofi S.A Company Details
    • 11.2.2 Sanofi S.A Business Overview
    • 11.2.3 Sanofi S.A Hormone Refractory Prostate Cancer (HRPCA) Introduction
    • 11.2.4 Sanofi S.A Revenue in Hormone Refractory Prostate Cancer (HRPCA) Business (2016-2021)
    • 11.2.5 Sanofi S.A Recent Development
  • 11.3 Dendreon Corporation, Bayer AG
    • 11.3.1 Dendreon Corporation, Bayer AG Company Details
    • 11.3.2 Dendreon Corporation, Bayer AG Business Overview
    • 11.3.3 Dendreon Corporation, Bayer AG Hormone Refractory Prostate Cancer (HRPCA) Introduction
    • 11.3.4 Dendreon Corporation, Bayer AG Revenue in Hormone Refractory Prostate Cancer (HRPCA) Business (2016-2021)
    • 11.3.5 Dendreon Corporation, Bayer AG Recent Development
  • 11.4 Johnson & Johnson
    • 11.4.1 Johnson & Johnson Company Details
    • 11.4.2 Johnson & Johnson Business Overview
    • 11.4.3 Johnson & Johnson Hormone Refractory Prostate Cancer (HRPCA) Introduction
    • 11.4.4 Johnson & Johnson Revenue in Hormone Refractory Prostate Cancer (HRPCA) Business (2016-2021)
    • 11.4.5 Johnson & Johnson Recent Development

12 Analyst's Viewpoints/Conclusions

    13 Appendix

    • 13.1 Research Methodology
      • 13.1.1 Methodology/Research Approach
      • 13.1.2 Data Source
    • 13.2 Disclaimer

    Hormone Refractory Prostate Cancer (HRPCA) market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Hormone Refractory Prostate Cancer (HRPCA) market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2016-2027.

    Segment by Type
    Cytotoxic Agents
    Anti-Androgens
    Vaccines
    Radio-Pharmaceuticals

    Segment by Application
    Hospitals
    Ambulatory Surgical Centers
    Specialty Clinics
    Others

    By Region
    North America
    U.S.
    Canada
    Europe
    Germany
    France
    U.K.
    Italy
    Russia
    Nordic
    Rest of Europe
    Asia-Pacific
    China
    Japan
    South Korea
    Southeast Asia
    India
    Australia
    Rest of Asia
    Latin America
    Mexico
    Brazil
    Rest of Latin America
    Middle East & Africa
    Turkey
    Saudi Arabia
    UAE
    Rest of MEA

    By Company
    Astellas Inc
    Sanofi S.A
    Dendreon Corporation, Bayer AG
    Johnson & Johnson

    Buy now